Clinical features and demography of patients with severe acute respiratory syndrome(SARS) and control patients (univariate)
| SARS | Controls | Odds ratio (95% CI)# | p-value¶ | |
| Subjects n | 44 | 251 | ||
| Mean age yrs | 39.27±11.26 | 42.04±12.49 | 0.982 (0.956–1.008) | 0.172 |
| Sex male | 22 | 140 | 0.79 (0.42–1.51) | 0.478 |
| Epidemiological linkage | 32 | 18 | 34.52 (15.22–78.26) | 0.000 |
| Clinical symptoms (day 1–3) | ||||
| Cough | 19 | 163 | 0.41 (0.21–0.79) | 0.007 |
| Sputum production | 6 | 97 | 0.25 (0.10–0.62) | 0.003 |
| Dyspnoea | 6 | 41 | 0.81 (0.32–2.04) | 0.652 |
| Myalgia | 22 | 75 | 2.35 (1.23–4.49) | 0.010 |
| Chills | 25 | 99 | 2.02 (1.06–3.86) | 0.033 |
| Fever (38°C) or history of fever within 48 h before admission | 43 | 227 | 4.55 (0.60–34.51) | 0.143 |
| Upper respiratory tract symptoms | 10 | 71 | 0.75 (0.35–1.59) | 0.447 |
| Gastrointestinal symptoms | 9 | 44 | 1.21 (0.54–2.70) | 0.642 |
| Laboratory parameters | ||||
| Thrombocytopenia day 1–3 | 17 | 41 | 3.22 (1.61–6.45) | 0.001 |
| Leukocytosis day 1–3 | 11 | 85 | 0.65 (0.31–1.35) | 0.250 |
| Lymphocytopenia day 1–3 | 38 | 143 | 4.78 (1.95–11.72) | 0.001 |
| Elevated alanine transaminase day 1–3 | 31 | 103 | 3.43 (1.71–6.86) | 0.001 |
| Chest radiographic progress comparing day 1 to day 3 | ||||
| Unchanged | 17 | 178 | 0.26 (0.13–0.53) | <0.001 |
| Deterioration | 26 | 35 | 8.91 (4.2–19.07) | <0.001 |
| Improvement | 1 | 38 | 0.13 (0.01–0.92) | 0.02 |
Data presented as n or mean±sd, unless otherwise stated. Refer to methods for definitions of epidemiological linkage, clinical symptoms, laboratory parameters and radiographical evaluation. 95% CI: 95% confidence interval. #: obtained by comparing SARS with control patients; ¶: obtained on univariate comparison between SARS patients and controls.